Aquinox Pharmaceuticals (NASDAQ:AQXP) has been assigned a $22.00 price target by stock analysts at Canaccord Genuity in a research note issued on Monday. The firm currently has a “buy” rating on the stock. Canaccord Genuity’s target price points to a potential upside of 108.14% from the stock’s current price.

AQXP has been the topic of several other reports. Zacks Investment Research downgraded Aquinox Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, August 15th. Cantor Fitzgerald reiterated a “buy” rating and issued a $28.00 target price on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Aquinox Pharmaceuticals in a research note on Thursday, November 9th. Finally, ValuEngine cut shares of Aquinox Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Friday, September 15th. Two research analysts have rated the stock with a sell rating, one has given a hold rating and three have given a buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $22.50.

Shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) traded down $0.03 during trading hours on Monday, hitting $10.57. The stock had a trading volume of 95,500 shares, compared to its average volume of 85,455. Aquinox Pharmaceuticals has a 12 month low of $10.20 and a 12 month high of $19.97.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Alyeska Investment Group L.P. lifted its stake in shares of Aquinox Pharmaceuticals by 1.8% in the third quarter. Alyeska Investment Group L.P. now owns 282,569 shares of the company’s stock valued at $4,010,000 after buying an additional 5,046 shares during the period. Vanguard Group Inc. lifted its stake in Aquinox Pharmaceuticals by 6.6% during the second quarter. Vanguard Group Inc. now owns 282,483 shares of the company’s stock worth $3,974,000 after purchasing an additional 17,455 shares during the period. University of Notre Dame DU Lac lifted its stake in Aquinox Pharmaceuticals by 11.1% during the third quarter. University of Notre Dame DU Lac now owns 190,283 shares of the company’s stock worth $2,700,000 after purchasing an additional 19,066 shares during the period. Geode Capital Management LLC lifted its stake in Aquinox Pharmaceuticals by 10.0% during the first quarter. Geode Capital Management LLC now owns 121,532 shares of the company’s stock worth $2,028,000 after purchasing an additional 11,035 shares during the period. Finally, Nexthera Capital LP bought a new position in Aquinox Pharmaceuticals during the second quarter worth about $1,276,000. Institutional investors and hedge funds own 96.25% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Aquinox Pharmaceuticals (AQXP) Given a $22.00 Price Target by Canaccord Genuity Analysts” was reported by Watch List News and is the property of of Watch List News. If you are reading this news story on another domain, it was illegally copied and republished in violation of United States and international trademark & copyright law. The correct version of this news story can be read at https://www.watchlistnews.com/aquinox-pharmaceuticals-aqxp-given-a-22-00-price-target-by-canaccord-genuity-analysts/1757434.html.

Aquinox Pharmaceuticals Company Profile

Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.

Receive News & Ratings for Aquinox Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.